GHRP-2 is a synthetic hexapeptide belonging to the growth hormone-releasing peptide family, studied in the literature as a ghrelin receptor (GHS-R1a) agonist. AminoOptimization Group supplies it as a lyophilised research powder in a 10 mg presentation, tested to 99% purity by HPLC, with a Certificate of Analysis available for the lot supplied. This material is offered strictly for laboratory research use. It is not a drug, and it is not for human or veterinary use.
What is GHRP-2?
GHRP-2 (D-Ala-D-2-methylTrp-Ala-Trp-D-Phe-Lys-NH2), also known in the pharmacological literature under the INN pralmorelin, is a hexapeptide built from a mix of D- and L-amino acids and terminating in a C-terminal amide rather than a free carboxylic acid. It is classified as a growth hormone secretagogue: a molecule that engages the growth hormone secretagogue receptor (GHS-R1a), the same receptor family targeted by the endogenous peptide ghrelin. Where ghrelin’s activity at GHS-R1a depends on a serine-3 octanoylation, GHRP-2 is reported to bind and activate the receptor without that fatty-acid modification — a property the literature attributes to the non-natural 2-methyltryptophan residue and the D-amino acid substitutions in the sequence, which are also described as conferring greater resistance to proteolytic cleavage than a comparable all-L-amino-acid chain.
Because GHRP-2 acts at GHS-R1a rather than at the growth hormone-releasing hormone receptor, it is structurally and mechanistically distinct from GHRH analogues such as sermorelin or CJC-1295 variants, and it is frequently examined alongside them in study designs that probe how the two receptor pathways interact. It is also compared within its own structural family — against GHRP-6 and hexarelin in particular — in literature addressing receptor binding characteristics and the relative magnitude of co-released hormones observed in model systems.
Specifications
- Compound: GHRP-2 (Pralmorelin)
- CAS number: 158861-67-7
- Molecular formula: C45H55N9O6
- Molecular weight: 817.93 g/mol
- Purity: 99% by HPLC
- Presentation: Lyophilised powder, sealed vial
- Available sizes: 10 mg
- Physical form: White to off-white powder
- Classification: Research peptide — not for human or veterinary use
Research context
Published research on GHRP-2 focuses on its action at the growth hormone secretagogue receptor and the downstream signalling this agonism produces within the somatotropic axis. Because GHS-R1a is expressed at both the hypothalamic and pituitary level, study designs have examined stimulation at each site independently, as well as combined administration with GHRH-receptor agonists to characterise additive or synergistic secretion patterns in model systems.
Comparative literature also situates GHRP-2 against other members of the growth hormone-releasing peptide family. Since ghrelin itself requires octanoylation for GHS-R1a activity, GHRP-2’s non-acylated engagement of the same receptor makes it a tool compound in signalling studies that aim to isolate receptor-level effects from the metabolic regulation surrounding ghrelin’s own acylation.
None of this literature establishes safety or efficacy for use in humans. It is provided as research context only.
Reconstitution
Lyophilised peptide requires reconstitution with a suitable sterile diluent before use in solution. Bacteriostatic water is the diluent most commonly specified for multi-use laboratory preparations; sterile water is typical for single-use work.
Direct the diluent stream against the inner wall of the vial rather than onto the powder itself, and allow the material to dissolve without agitation. Peptides are susceptible to shear stress — do not shake the vial. Swirl gently if needed, and expect full dissolution within a few minutes at room temperature.
Working concentration is a function of how much diluent is added to a given vial mass. Our peptide reconstitution calculator computes the resulting concentration for any combination of vial size and diluent volume.
Storage and stability
Before reconstitution: store the sealed vial in a freezer at -20 °C, protected from light. Lyophilised peptide is comparatively stable in this state. Brief excursions to ambient temperature during shipping are normal and are not expected to compromise a properly lyophilised product.
After reconstitution: refrigerate at 2–8 °C and protect from light. Reconstituted peptide in solution is materially less stable than the dry powder. Avoid repeated freeze-thaw cycles, which are a well-documented cause of aggregation and loss of measurable potency — aliquot instead if repeated sampling is required.
Inspect solutions before use. Cloudiness, visible particulate, or discolouration indicate the material should not be relied upon for quantitative work.
Certificate of Analysis
Every lot is tested by high-performance liquid chromatography, and the purity figure shown above refers to analytical results for the specific lot supplied — not to a generic specification. A Certificate of Analysis is available on request, and we will provide lot-specific documentation before purchase if your protocol requires it.
Purity by HPLC describes the proportion of the target peptide relative to detectable related substances. It is a statement about the material as manufactured and tested. It is expressly not a representation that the material is suitable for any use in humans or animals.
Handling and safety
Handle in accordance with good laboratory practice. Use appropriate personal protective equipment, work in a suitable containment environment, and dispose of material and consumables according to your institution’s requirements and applicable local regulation. Anyone with access to this material should understand that it is not for human or veterinary use.
Frequently asked questions
What is the difference between GHRP-2 and GHRP-6?
Both are hexapeptide secretagogues acting at the growth hormone secretagogue receptor (GHS-R1a), but they differ in sequence: GHRP-2 carries a D-alanine and a 2-methyl-D-tryptophan at the N-terminal end, where GHRP-6 carries a free D-tryptophan. Comparative literature reports differences between the two in receptor binding characteristics and in the magnitude of co-released hormones such as cortisol and prolactin observed in model systems.
Is GHRP-2 approved in Canada?
No. This compound has not been evaluated or authorised by Health Canada, the FDA, or any comparable regulatory authority. It carries no DIN or NPN, its safety and efficacy for human use have not been assessed, and it is supplied for laboratory research only.
How much diluent should be used?
That depends on the working concentration your protocol requires. Use the reconstitution calculator to work out the resulting concentration for your vial size.
How long is reconstituted material usable?
Stability in solution is shorter than in lyophilised form and depends on diluent, temperature, and handling. Refrigerate at 2–8 °C, protect from light, avoid freeze-thaw cycling, and validate stability for your own storage conditions if your work depends on it.
Do you provide a Certificate of Analysis?
Yes — lot-specific, available on request, including before purchase.
Research use only
This product is supplied solely for laboratory and scientific research. It is not a drug, food, cosmetic, or medical device, and it must not be administered to humans or animals. Nothing on this page is medical advice or a therapeutic claim. Full terms are set out in our Research Use Only Disclaimer.
Reviews
There are no reviews yet.